Vera Therapeutics, Inc. has announced the pricing of an underwritten public offering of 6,138,108 shares of its Class A common stock at $42.50 per share. The gross proceeds are expected to be around $261 million, with an option to purchase additional shares. The offering is set to close on December 11, 2025, with J.P. Morgan, Goldman Sachs, Evercore ISI, and Cantor as joint book-running managers. Vera Therapeutics focuses on developing treatments for serious immunological diseases, with their lead product candidate being atacicept, a fusion protein targeting autoimmune diseases like IgAN and lupus nephritis.

This press release does not constitute an offer to sell or solicitation to buy securities from Vera Therapeutics. The company aims to change the standard of care for patients with serious immunological diseases. Vera Therapeutics’ lead product candidate is atacicept, a self-administered injection that blocks B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL) to combat autoimmune diseases. They have an exclusive license agreement with Stanford University for a fusion protein known as VT-109 and are also developing MAU868, a monoclonal antibody to neutralize BK virus infection in kidney transplant recipients.

Read more at GlobeNewswire: Vera Therapeutics Announces Pricing of Public Offering of